Jade Bios reports potent preclinical JADE301 data, 30-day NHP half-life and Phase 1 start planned

Jade Bios announced preclinical data showing JADE301 potently neutralizes IFN-ß and supports infrequent subcutaneous dosing.Key Highlights:Original SEC Filing: Jade Biosciences, Inc. [ JBIO ] - 8-K - Sep. 30, 2026This is an AI-powered summary. It may contain inaccuracies. Consider verifying importa…